84例巨大催乳素瘤患者的长期随访——一项瑞典全国性研究
该研究基于瑞典垂体登记库1991-2018年数据,纳入84例巨大催乳素瘤患者(血清催乳素>1000 µg/L,肿瘤直径≥40 mm),描述其临床表现与治疗结局。所有患者均接受过多巴胺激动剂治疗,27%需额外治疗;末次随访时55%催乳素正常化,69%肿瘤显著缩小,43%达到联合应答。作者认为治疗1年时的反应有助于识别需更密切监测及可能需额外治疗的患者。
要点
- 巨大催乳素瘤诊断时84%存在促性腺激素性性腺功能减退,71%有视野缺损。
- 所有患者均接受多巴胺激动剂治疗,27%需手术、放疗等其他治疗。
- 末次随访中位9年时,55%催乳素正常化,69%肿瘤显著缩小,43%联合应答。
核心结论
- 多巴胺激动剂可有效降低催乳素和缩小肿瘤,但约四分之一患者需要多模式治疗。
- 作者认为治疗1年时对多巴胺激动剂的反应有助于识别需要更密切监测及在某些情况下需额外治疗的患者。
研究设计与样本
- 基于瑞典垂体登记库1991-2018年的登记研究,纳入巨大催乳素瘤患者(血清催乳素>1000 µg/L,肿瘤直径≥40 mm)。
- 共纳入84例患者,平均年龄47岁(标准差±16),男性占89%。
主要发现
- 诊断时中位催乳素为6305 µg/L(范围1450-253000),中位肿瘤直径为47 mm(范围40-85)。
- 诊断时84%的患者有促性腺激素性性腺功能减退,71%有视野缺损。
- 所有患者均在某时接受过多巴胺激动剂治疗;23例(27%)接受1种或以上额外治疗,包括手术(n=19)、放疗(n=6)、其他药物治疗(n=4)和化疗(n=2)。
- 14例肿瘤中4例Ki-67≥10%。
- 末次随访中位9年(四分位距4-15)时,中位催乳素为12 µg/L(四分位距4-126),中位肿瘤直径为22 mm(四分位距3-40)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To describe the clinical presentation and treatment outcomes in a nationwide cohort of patients with giant prolactinomas. METHODS: Register-based study of patients with giant prolactinomas [serum prolactin (PRL) > 1000 µg/L, tumor diameter ≥40 mm] identified in the Swedish Pituitary Register 1991-2018. RESULTS: Eighty-four patients [mean age 47 (SD ±16) years, 89% men] were included in the study. At diagnosis, the median PRL was 6305 µg/L (range 1450-253 000), the median tumor diameter was 47 mm (range 40-85), 84% of the patients had hypogonadotropic hypogonadism, and 71% visual field defects. All patients were treated with a dopamine agonist (DA) at some point. Twenty-three (27%) received 1 or more additional therapies, including surgery (n = 19), radiotherapy (n = 6), other medical treatments (n = 4), and chemotherapy (n = 2). Ki-67 was ≥10% in 4/14 tumors. At the last follow-up [median 9 years (interquartile range (IQR) 4-15)], the median PRL was 12 µg/L (IQR 4-126), and the median tumor diameter was 22 mm (IQR 3-40). Normalized PRL was achieved in 55%, significant tumor reduction in 69%, and combined response (normalized PRL and significant tumor reduction) in 43%. In the primary DA-treated patients (n = 79), the reduction in PRL or tumor size after the first year predicted the combined response at the last follow-up (P < .001 and P = .012, respectively). CONCLUSION: DAs effectively reduced PRL and tumor size, but approximately 1 patient out of 4 needed multimodal treatment. Our results suggest that the response to DA after 1 year is useful for identifying patients who need more careful monitoring and, in some cases, additional treatment.
引用
- Himonakos C, Burman P, Borg H, et al. Long-term Follow-up of 84 Patients With Giant Prolactinomas-A Swedish Nationwide Study. J Clin Endocrinol Metab. 2023. PMID: 37403202. doi:10.1210/clinem/dgad393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。